We are live on ! Find out more
CLLS

Cellectis

31 hedge funds and large institutions have $18.1M invested in Cellectis in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $6K | Put options by funds: $1K

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

4.55% less ownership

Funds ownership: 25.2%20.66% (-4.5%)

14% less funds holding

Funds holding: 3631 (-5)

34% less capital invested

Capital invested by funds: $27.6M → $18.1M (-$9.45M)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
31
Holders Change
-5
Holders Change %
-13.89%
% of All Funds
0.49%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
2
Increased
8
Reduced
6
Closed
7
Calls
$6K
Puts
$1K
Net Calls
+$5K
Net Calls Change
-$4K

CLLS Hedge Fund Activity: Q3 2023 in Review

31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q3 2023, worth a combined $18.1M — down 34% from $27.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CLLS and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 8 added.

The largest buyer was LPL Financial, adding an estimated $97K. The largest seller was Bpifrance, exiting entirely with an estimated $4.3M sold.

  • 31 institutional investors held Cellectis (CLLS) as of Q3 2023, down from 36 in Q2 2023.
  • Funds reported $18.1M of Cellectis stock for Q3 2023, down 34% quarter-over-quarter.
  • 2 funds opened new Cellectis positions in Q3 2023 and 7 closed out, a net change of -5 holders.
  • The largest Cellectis buyer in Q3 2023 was LPL Financial, an estimated $97K added.
  • The largest Cellectis seller in Q3 2023 was Bpifrance, an estimated $4.3M sold.

Based on aggregated 13F filings for Q3 2023.